Cyclosporin A treatment of young children with newly-diagnosed Type 1 (insulin-dependent) diabetes mellitus

✍ Scribed by M. Jenner; G. Bradish; C. Stiller; P. Atkison; The London Diabetes Study Group

• Publisher: Springer
• Year: 1992
• Tongue: English
• Weight: 629 KB
• Volume: 35
• Category: Article
• ISSN: 0012-186X
• DOI: 10.1007/bf00399937

✦ Synopsis

Several studies have demonstrated the efficacy of cyclosporin A in modifying the initial course of Type 1 (insulin-dependent) diabetes mellitus in older children and adults but none have reported the effects in very young children. We treated 14 newly-diagnosed Type 1 diabetic patients aged 22 months to 95 months with cyclosporin A. Mean insulin dose at entry was 0.7 _+ 0.07 IU-kg-l -day -t. Initial cyclosporinA dose was 10mg.kg-l.day -1. Insulin dose reached a nadir of 0.13 IU. kg-1. day-z by 180 days. Mean glucagon-stimulated connecting peptide levels were maximal at 6 months (0.75 nmol/1) and were maintained while on cyclosporin A. Insulin was discontinued in fourpatients for4,12,15 and 30 months respectively. In five other patients the insulin dose was less than 0.15 IU. kg-I day-~ for at least 3 months. Glycated haemoglobin levels for all patients were within the normal range. Side effects included anorexia, stomach pains, poor weight gain, hypertrichosis, gum hyperplasia, mild anaemia and elevated creatinine. All patients have now dis-